Although, the addition of GF109203X, a pan-PKC inhibitor was found to efficiently decrease the viability of myeloma cells, thereby suggesting that PKCs associated with MARCKS activation and drug resistance may be context-dependent in view of the heterogeneity of the pathophysiology among the patients [18]. Here, PRRT2 is linked to plasma cell myeloma.